Pharma’s Secret Middlemen Are Poisoning Health Care
Following a lobbying blitz, Congress might punt all efforts to stop shadowy pharmacy benefit managers from inflating drug prices and killing small pharmacies.
Deep dives into the political corruption and corporate bureaucracy that keeps Americans sick while making executives rich.
Following a lobbying blitz, Congress might punt all efforts to stop shadowy pharmacy benefit managers from inflating drug prices and killing small pharmacies.
Plus, Oregon aims to limit corporate takeover of medical clinics, federal regulators investigate private use of corporate aircrafts, and more student debt relief is on the way.
Plus, consumers could be protected from insurer meltdowns, dueling communities reach rare agreement over water rights, and rural America scores access to clean water.
A bombshell report reveals that taxpayers spent billions developing medicines that drugmakers say shouldn’t face Medicare price negotiations.
The government is finally attempting to regulate overpriced drugs, but venture capital firms don’t want to lose their lucrative hold on life-saving pharmaceuticals.
Plus, funding arrives for cleaner energy technologies, insurers’ care-denial bots are put on notice, and regulators tackle an airborne killer.
Plus, more states make Big Oil pay for climate change, new consumer protection rules block junk fees, and the EPA strengthens regulations for forever chemicals.
There’s a basic conflict of interest at the heart of American health care. We need to break up the industry to fix it.
Plus, cancer vaccines work, states aim to tax the rich, and a fossil fuel project gets delayed.
Many health insurers’ online provider directories are inaccurate or out-of-date, to the detriment of patients and health care professionals alike.